A Double‐Blind, Placebo‐Controlled, Single‐Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HT‐101, an RNAi Therapeutic Targeting HBV Infection.
Saved in:
| Title: | A Double‐Blind, Placebo‐Controlled, Single‐Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HT‐101, an RNAi Therapeutic Targeting HBV Infection. |
|---|---|
| Authors: | Zhang, Jianxiong1 (AUTHOR), Li, Jiangshuo1 (AUTHOR), Wu, Le1 (AUTHOR), Song, Yuqin1 (AUTHOR), Li, Xiao1 (AUTHOR), Gao, Qiannan1 (AUTHOR), Wu, Jingxuan1 (AUTHOR), Wang, Dong2 (AUTHOR), Zhang, Zhipeng2 (AUTHOR), Zhang, Shanzhong2 (AUTHOR), Ding, Lijuan2 (AUTHOR), Ma, Yanqin2 (AUTHOR), Ma, Hong3 (AUTHOR), Jia, Jidong3 (AUTHOR), Dong, Ruihua1 (AUTHOR) ruihua_dong_rw@163.com |
| Source: | Clinical Pharmacology in Drug Development. Oct2025, Vol. 14 Issue 10, p754-763. 10p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2160763X |
|---|---|
| DOI: | 10.1002/cpdd.1569 |
